{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:59:34Z","timestamp":1793386774042,"version":"4.5.0"},"reference-count":116,"publisher":"American Medical Association (AMA)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2024,5,21]]},"abstract":"<jats:sec id=\"ab-jrv240008-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) consists of a group of pulmonary disorders characterized by inflammation and\/or fibrosis of the lung parenchyma associated with progressive dyspnea that frequently results in end-stage respiratory failure. In the US, ILD affects approximately 650\u202f000 people and causes approximately 25\u202f000 to 30\u202f000 deaths per year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240008-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>The most common forms of ILD are idiopathic pulmonary fibrosis (IPF), which accounts for approximately one-third of all cases of ILD, hypersensitivity pneumonitis, accounting for 15% of ILD cases, and connective tissue disease (CTD), accounting for 25% of ILD cases. ILD typically presents with dyspnea on exertion. Approximately 30% of patients with ILD report cough. Thoracic computed tomography is approximately 91% sensitive and 71% specific for diagnosing subtypes of ILDs such as IPF. Physiologic assessment provides important prognostic information. A 5% decline in forced vital capacity (FVC) over 12 months is associated with an approximately 2-fold increase in mortality compared with no change in FVC. Antifibrotic therapy with nintedanib or pirfenidone slows annual FVC decline by approximately 44% to 57% in individuals with IPF, scleroderma associated ILD, and in those with progressive pulmonary fibrosis of any cause. For connective tissue disease\u2013associated ILD, immunomodulatory therapy, such as tocilizumab, rituximab, and mycophenolate mofetil, may slow decline or even improve FVC at 12-month follow-up. Structured exercise therapy reduces symptoms and improves 6-minute walk test distance in individuals with dyspnea. Oxygen reduces symptoms and improves quality of life in individuals with ILD who desaturate below 88% on a 6-minute walk test. Lung transplant may improve symptoms and resolve respiratory failure in patients with end-stage ILD. After lung transplant, patients with ILD have a median survival of 5.2 to 6.7 years compared with a median survival of less than 2 years in patients with advanced ILD who do not undergo lung transplant. Up to 85% of individuals with end-stage fibrotic ILD develop pulmonary hypertension. In these patients, treatment with inhaled treprostinil improves walking distance and respiratory symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv240008-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Interstitial lung disease typically presents with dyspnea on exertion and can progress to respiratory failure. First-line therapy includes nintedanib or pirfenidone for IPF and mycophenolate mofetil for ILD due to connective tissue disease. Lung transplant should be considered for patients with advanced ILD. In patients with ILD, exercise training improves 6-minute walk test distance and quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2024.3669","type":"journal-article","created":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T11:32:19Z","timestamp":1713785539000},"page":"1655","source":"Crossref","is-referenced-by-count":418,"title":["Interstitial Lung Disease"],"prefix":"10.1001","volume":"331","author":[{"given":"Toby M.","family":"Maher","sequence":"first","affiliation":[{"name":"University of Southern California, Los Angeles"},{"name":"National Heart and Lung Institute, Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"jrv240008r1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease.","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv240008r2","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00630-2021","article-title":"The prevalence and burden of interstitial lung diseases in the USA.","volume":"8","author":"Jeganathan","year":"2021","journal-title":"ERJ Open Res"},{"issue":"6","key":"jrv240008r3","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"jrv240008r4","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline.","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv240008r5","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1164\/rccm.202201-0124OC","article-title":"Validation of proposed criteria for progressive pulmonary fibrosis.","volume":"207","author":"Pugashetti","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv240008r6","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.chest.2020.02.009","article-title":"Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study.","volume":"158","author":"Zaman","year":"2020","journal-title":"Chest"},{"issue":"1","key":"jrv240008r7","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s12931-021-01791-z","article-title":"Global incidence and prevalence of idiopathic pulmonary fibrosis.","volume":"22","author":"Maher","year":"2021","journal-title":"Respir Res"},{"issue":"2","key":"jrv240008r8","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1513\/AnnalsATS.202103-295OC","article-title":"Epidemiology of idiopathic pulmonary fibrosis among U.S. veterans, 2010-2019.","volume":"19","author":"Kaul","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"jrv240008r9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1183\/09031936.00185114","article-title":"Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review.","volume":"46","author":"Hutchinson","year":"2015","journal-title":"Eur Respir J"},{"issue":"8997","key":"jrv240008r10","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S0140-6736(96)90465-1","article-title":"Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis.","volume":"347","author":"Hubbard","year":"1996","journal-title":"Lancet"},{"issue":"7","key":"jrv240008r11","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1080\/10937404.2022.2131663","article-title":"Idiopathic pulmonary fibrosis: what do we know about the role of occupational and environmental determinants? a systematic literature review and meta-analysis.","volume":"25","author":"Pauchet","year":"2022","journal-title":"J Toxicol Environ Health B Crit Rev"},{"issue":"10","key":"jrv240008r12","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1136\/thoraxjnl-2019-214478","article-title":"Occupational and environmental risk factors for idiopathic pulmonary fibrosis in Australia: case-control study.","volume":"75","author":"Abramson","year":"2020","journal-title":"Thorax"},{"issue":"1","key":"jrv240008r13","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00397-2017","article-title":"The association between air pollution and the incidence of idiopathic pulmonary fibrosis in Northern Italy.","volume":"51","author":"Conti","year":"2018","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv240008r14","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1513\/AnnalsATS.201704-288OC","article-title":"Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis.","volume":"15","author":"Fern\u00e1ndez P\u00e9rez","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"jrv240008r15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/acr.v64.4","article-title":"Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis.","volume":"64","author":"Steele","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"jrv240008r16","doi-asserted-by":"publisher","first-page":"3480","DOI":"10.1007\/s00330-021-08411-w","article-title":"Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies.","volume":"32","author":"Laporte","year":"2022","journal-title":"Eur Radiol"},{"issue":"6","key":"jrv240008r17","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.chest.2023.01.031","article-title":"Diagnosis and management of myositis-associated lung disease.","volume":"163","author":"Hallowell","year":"2023","journal-title":"Chest"},{"issue":"8","key":"jrv240008r18","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/resp.v27.8","article-title":"Epidemiology of interstitial lung disease in systemic lupus erythematosus in France: a nation-wide population-based study over 10?years.","volume":"27","author":"Mageau","year":"2022","journal-title":"Respirology"},{"issue":"10","key":"jrv240008r19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis.","volume":"156","author":"Ley","year":"2012","journal-title":"Ann Intern Med"},{"issue":"9","key":"jrv240008r20","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1164\/rccm.202207-1331OC","article-title":"Idiopathic pulmonary fibrosis is associated with common genetic variants and limited rare variants.","volume":"207","author":"Peljto","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"jrv240008r21","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.chest.2023.05.013","article-title":"Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung Disease.","volume":"164","author":"Myall","year":"2023","journal-title":"Chest"},{"issue":"9","key":"jrv240008r22","doi-asserted-by":"publisher","first-page":"641","DOI":"10.7326\/0003-4819-158-9-201305070-00003","article-title":"Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial.","volume":"158","author":"Raghu","year":"2013","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv240008r23","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1183\/13993003.01537-2014","article-title":"Pulmonary hypertension in idiopathic pulmonary fibrosis with mild-to-moderate restriction.","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv240008r24","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1183\/13993003.02316-2014","article-title":"Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review.","volume":"46","author":"Raghu","year":"2015","journal-title":"Eur Respir J"},{"issue":"5","key":"jrv240008r25","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/res.2009.14.issue-5","article-title":"Cumulative incidence of and predictive factors for lung cancer in IPF.","volume":"14","author":"Ozawa","year":"2009","journal-title":"Respirology"},{"issue":"1","key":"jrv240008r26","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00111-2016","article-title":"Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis.","volume":"4","author":"Kato","year":"2018","journal-title":"ERJ Open Res"},{"issue":"3","key":"jrv240008r27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. an international working group report.","volume":"194","author":"Collard","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv240008r28","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1183\/09031936.00159709","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.","volume":"37","author":"Song","year":"2011","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv240008r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000563","article-title":"Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases.","volume":"7","author":"Salonen","year":"2020","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"jrv240008r30","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1165\/rcmb.2020-0373PS","article-title":"The interplay of the genetic architecture, aging, and environmental factors in the pathogenesis of idiopathic pulmonary fibrosis.","volume":"64","author":"Pardo","year":"2021","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"10","key":"jrv240008r31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1164\/rccm.201908-1571OC","article-title":"Interstitial lung disease in relatives of patients with pulmonary fibrosis.","volume":"201","author":"Hunninghake","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"jrv240008r32","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1164\/rccm.201905-1017OC","article-title":"Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis.","volume":"201","author":"Allen","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv240008r33","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/ng.2609","article-title":"Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis.","volume":"45","author":"Fingerlin","year":"2013","journal-title":"Nat Genet"},{"issue":"2","key":"jrv240008r34","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/all.v77.2","article-title":"Hypersensitivity pneumonitis: current concepts in pathogenesis, diagnosis, and treatment.","volume":"77","author":"Barnes","year":"2022","journal-title":"Allergy"},{"issue":"5","key":"jrv240008r35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/thoraxjnl-2021-217693","article-title":"Common idiopathic pulmonary fibrosis risk variants are associated with hypersensitivity pneumonitis.","volume":"77","author":"Furusawa","year":"2022","journal-title":"Thorax"},{"key":"jrv240008r36","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X211032457","article-title":"Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders.","author":"Kuwana","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"23","key":"jrv240008r37","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1801562","article-title":"MUC5B promoter variant and rheumatoid arthritis with interstitial lung disease.","volume":"379","author":"Juge","year":"2018","journal-title":"N Engl J Med"},{"issue":"129","key":"jrv240008r38","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1183\/09059180.00000713","article-title":"The role of infection in the pathogenesis of idiopathic pulmonary fibrosis.","volume":"22","author":"Molyneaux","year":"2013","journal-title":"Eur Respir Rev"},{"issue":"10","key":"jrv240008r39","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3390\/jcm7100356","article-title":"Drug-induced interstitial lung disease: a systematic review.","volume":"7","author":"Skeoch","year":"2018","journal-title":"J Clin Med"},{"issue":"2","key":"jrv240008r40","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00050-2017","article-title":"Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.","volume":"50","author":"Delaunay","year":"2017","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv240008r41","doi-asserted-by":"publisher","first-page":"13773","DOI":"10.1038\/s41598-020-70743-2","article-title":"Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.","volume":"10","author":"Okada","year":"2020","journal-title":"Sci Rep"},{"issue":"6","key":"jrv240008r42","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1164\/rccm.202203-0564OC","article-title":"Residual lung abnormalities after COVID-19 hospitalization: interim analysis of the UKILD post-COVID-19 study.","volume":"207","author":"Stewart","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"jrv240008r43","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMc2117024","article-title":"Lung transplantation for COVID-19-related respiratory failure in the United States.","volume":"386","author":"Roach","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv240008r44","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1111\/res.2010.15.issue-3","article-title":"The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status.","volume":"15","author":"Ngai","year":"2010","journal-title":"Respirology"},{"key":"jrv240008r45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41413-020-0084-5","article-title":"Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study.","volume":"8","author":"Zhang","year":"2020","journal-title":"Bone Res"},{"issue":"9","key":"jrv240008r46","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1513\/AnnalsATS.202302-174OC","article-title":"The burden and impact of cough in patients with idiopathic pulmonary fibrosis: an analysis of the prospective observational PROFILE study.","volume":"20","author":"Saunders","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"jrv240008r47","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01289-2018","article-title":"Weight loss as a predictor of mortality in patients with interstitial lung disease.","volume":"52","author":"Pugashetti","year":"2018","journal-title":"Eur Respir J"},{"issue":"1","key":"jrv240008r48","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12931-023-02371-z","article-title":"Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial.","volume":"24","author":"Kreuter","year":"2023","journal-title":"Respir Res"},{"issue":"2","key":"jrv240008r49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.55563\/clinexprheumatol\/brvl1v","article-title":"Myositis-associated interstitial lung disease: a comprehensive approach to diagnosis and management.","volume":"40","author":"Hallowell","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"jrv240008r50","doi-asserted-by":"publisher","first-page":"iii3","DOI":"10.1093\/rheumatology\/kel282","article-title":"Epidemiology of connective tissue disorders.","volume":"45","author":"Gaubitz","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"jrv240008r51","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.rmed.2017.10.021","article-title":"Clubbing in patients with fibrotic interstitial lung diseases.","volume":"132","author":"van Manen","year":"2017","journal-title":"Respir Med"},{"issue":"1","key":"jrv240008r52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2020-000815","article-title":"Fine crackles on chest auscultation in the early diagnosis of idiopathic pulmonary fibrosis: a prospective cohort study.","volume":"8","author":"Moran-Mendoza","year":"2021","journal-title":"BMJ Open Respir Res"},{"issue":"11","key":"jrv240008r53","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1513\/AnnalsATS.202112-1377RL","article-title":"Diagnostic accuracy of chest radiography for detecting fibrotic interstitial lung disease.","volume":"19","author":"Ghodrati","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"jrv240008r54","doi-asserted-by":"publisher","first-page":"390","DOI":"10.5114\/ceji.2019.92791","article-title":"The value of serum precipitins against specific antigens in patients diagnosed with hypersensitivity pneumonitis - retrospective study.","volume":"44","author":"Szturmowicz","year":"2019","journal-title":"Cent Eur J Immunol"},{"issue":"9","key":"jrv240008r55","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1164\/ajrccm.164.9.2103074","article-title":"Histopathologic variability in usual and nonspecific interstitial pneumonias.","volume":"164","author":"Flaherty","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"jrv240008r56","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1164\/rccm.200402-147OC","article-title":"Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?","volume":"170","author":"Flaherty","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"jrv240008r57","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201508-1632OC","article-title":"In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. 2000 to 2011.","volume":"193","author":"Hutchinson","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"jrv240008r58","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1183\/13993003.01633-2016","article-title":"Lung biopsy in interstitial lung disease: balancing the risk of surgery and diagnostic uncertainty.","volume":"48","author":"Cottin","year":"2016","journal-title":"Eur Respir J"},{"issue":"2","key":"jrv240008r59","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/S2213-2600(19)30342-X","article-title":"Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study.","volume":"8","author":"Troy","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"7","key":"jrv240008r60","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1513\/AnnalsATS.202102-198OC","article-title":"Transbronchial lung cryobiopsy in patients with interstitial lung disease: a systematic review.","volume":"19","author":"Kheir","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"jrv240008r61","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1183\/09031936.00131912","article-title":"Prevalence and prognosis of unclassifiable interstitial lung disease.","volume":"42","author":"Ryerson","year":"2013","journal-title":"Eur Respir J"},{"issue":"12","key":"jrv240008r62","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1111\/resp.v28.12","article-title":"Decline in forced vital capacity as a surrogate for mortality in patients with pulmonary fibrosis.","volume":"28","author":"Maher","year":"2023","journal-title":"Respirology"},{"issue":"8","key":"jrv240008r63","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1002\/art.v69.8","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis.","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"jrv240008r64","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1164\/rccm.201511-2152OC","article-title":"Daily home spirometry: an effective tool for detecting progression in idiopathic pulmonary fibrosis.","volume":"194","author":"Russell","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"jrv240008r65","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00155108","article-title":"Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.","volume":"35","author":"Zappala","year":"2010","journal-title":"Eur Respir J"},{"issue":"7","key":"jrv240008r66","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1358\/dot.2010.46.7.1488336","article-title":"Pirfenidone in idiopathic pulmonary fibrosis.","volume":"46","author":"Maher","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"22","key":"jrv240008r67","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.","volume":"370","author":"King","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240008r68","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1183\/13993003.00026-2015","article-title":"Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.","volume":"47","author":"Noble","year":"2016","journal-title":"Eur Respir J"},{"issue":"5","key":"jrv240008r69","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/S2213-2600(20)30554-3","article-title":"Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"2","key":"jrv240008r70","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/S2213-2600(19)30341-8","article-title":"Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.","volume":"8","author":"Maher","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"jrv240008r71","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S2213-2600(22)00260-0","article-title":"Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study.","volume":"11","author":"Solomon","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"22","key":"jrv240008r72","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.","volume":"370","author":"Richeldi","year":"2014","journal-title":"N Engl J Med"},{"issue":"26","key":"jrv240008r73","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease.","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240008r74","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S2213-2600(20)30330-1","article-title":"Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial.","volume":"9","author":"Highland","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"5","key":"jrv240008r75","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/S2213-2600(20)30036-9","article-title":"Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.","volume":"8","author":"Wells","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"1","key":"jrv240008r76","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397","article-title":"Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials.","volume":"6","author":"Lancaster","year":"2019","journal-title":"BMJ Open Respir Res"},{"issue":"10038","key":"jrv240008r77","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial.","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"jrv240008r78","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"25","key":"jrv240008r79","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease.","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"jrv240008r80","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"7","key":"jrv240008r81","doi-asserted-by":"publisher","first-page":"e489","DOI":"10.1016\/S2665-9913(21)00107-7","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.","volume":"3","author":"Ebata","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"21","key":"jrv240008r82","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMoa1113354","article-title":"Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.","volume":"366","author":"Raghu","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"jrv240008r83","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.","volume":"186","author":"Noth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"jrv240008r84","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1164\/rccm.200906-0964OC","article-title":"Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results.","volume":"181","author":"Daniels","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"9685","key":"jrv240008r85","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(09)60551-1","article-title":"Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.","volume":"374","author":"King","year":"2009","journal-title":"Lancet"},{"issue":"2","key":"jrv240008r86","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02442-2019","article-title":"Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis.","volume":"57","author":"Maher","year":"2021","journal-title":"Eur Respir J"},{"issue":"18","key":"jrv240008r87","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1001\/jama.2023.5355","article-title":"Ziritaxestat, a novel autotaxin inhibitor, and lung function in idiopathic pulmonary fibrosis: the ISABELA 1 and 2 randomized clinical trials.","volume":"329","author":"Maher","year":"2023","journal-title":"JAMA"},{"issue":"22","key":"jrv240008r88","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1001\/jama.2020.22960","article-title":"Effect of co-trimoxazole (trimethoprim-sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: the EME-TIPAC randomized clinical trial.","volume":"324","author":"Wilson","year":"2020","journal-title":"JAMA"},{"issue":"18","key":"jrv240008r89","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1001\/jama.2021.4956","article-title":"Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial.","volume":"325","author":"Martinez","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"jrv240008r90","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial.","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"jrv240008r91","doi-asserted-by":"publisher","first-page":"e36","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of hypersensitivity pneumonitis in adults: an official ATS\/JRS\/ALAT clinical practice guideline.","volume":"202","author":"Raghu","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"jrv240008r92","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s13075-015-0835-7","article-title":"Incidence and complications of interstitial lung disease in users of tocilizumab, rituximab, abatacept and anti-tumor necrosis factor a agents, a retrospective cohort study.","volume":"17","author":"Curtis","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"jrv240008r93","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs.","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open"},{"key":"jrv240008r94","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/ajt.15677","article-title":"OPTN\/SRTR 2018 annual data report: lung.","volume":"20","author":"Valapour","year":"2020","journal-title":"Am J Transplant"},{"issue":"3","key":"jrv240008r95","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/MOT.0000000000000753","article-title":"Survival in adult lung transplantation: where are we in 2020?","volume":"25","author":"Bos","year":"2020","journal-title":"Curr Opin Organ Transplant"},{"issue":"10","key":"jrv240008r96","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","article-title":"The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match.","volume":"38","author":"Chambers","year":"2019","journal-title":"J Heart Lung Transplant"},{"issue":"2","key":"jrv240008r97","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1164\/rccm.201403-0446OC","article-title":"Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia.","volume":"190","author":"Corte","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"jrv240008r98","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis.","volume":"363","author":"Zisman","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"jrv240008r99","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1164\/rccm.201903-0488OC","article-title":"Nintedanib and sildenafil in patients with idiopathic pulmonary fibrosis and right heart dysfunction. a prespecified subgroup analysis of a double-blind randomized clinical trial (INSTAGE).","volume":"200","author":"Behr","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv240008r100","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S2213-2600(20)30356-8","article-title":"Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial.","volume":"9","author":"Behr","year":"2021","journal-title":"Lancet Respir Med"},{"issue":"9","key":"jrv240008r101","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/S2213-2600(19)30250-4","article-title":"Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study.","volume":"7","author":"Nathan","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"2","key":"jrv240008r102","article-title":"Pulmonary rehabilitation for interstitial lung disease.","volume":"2","author":"Dowman","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"jrv240008r103","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S2213-2600(18)30289-3","article-title":"Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial.","volume":"6","author":"Visca","year":"2018","journal-title":"Lancet Respir Med"},{"key":"jrv240008r104","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202311-2169LE","article-title":"Cough severity visual analogue scale assesses cough burden and predicts survival in idiopathic pulmonary fibrosis.","author":"Wu","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"jrv240008r105","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/SPC.0000000000000509","article-title":"Use of short-acting opioids in the management of breathlessness: an evidence-based review.","volume":"14","author":"Hui","year":"2020","journal-title":"Curr Opin Support Palliat Care"},{"issue":"8","key":"jrv240008r106","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2300083","article-title":"Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis.","volume":"2","author":"Maher","year":"2023","journal-title":"NEJM Evid"},{"key":"jrv240008r107","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00432-0","article-title":"Morphine for treatment of cough in idiopathic pulmonary fibrosis (PACIFY COUGH): a prospective, multicentre, randomised, double-blind, placebo-controlled, two-way crossover trial.","author":"Wu","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"4","key":"jrv240008r108","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1164\/rccm.200607-892OC","article-title":"Opiate therapy in chronic cough.","volume":"175","author":"Morice","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"jrv240008r109","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00262-2017","article-title":"Contributions of a hand-held fan to self-management of chronic breathlessness.","volume":"50","author":"Luckett","year":"2017","journal-title":"Eur Respir J"},{"key":"jrv240008r110","article-title":"Treatment of systemic sclerosis-associated interstitial lung disease: evidence-based recommendations: an official American Thoracic Society Clinical Practice Guideline.","author":"Raghu","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"jrv240008r111","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00879-2022","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension.","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"11","key":"jrv240008r112","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1016\/j.healun.2021.07.005","article-title":"Consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation.","volume":"40","author":"Leard","year":"2021","journal-title":"J Heart Lung Transplant"},{"issue":"9","key":"jrv240008r113","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1513\/AnnalsATS.201606-458OC","article-title":"Acute exacerbation and decline in forced vital capacity are associated with increased mortality in idiopathic pulmonary fibrosis.","volume":"14","author":"Paterniti","year":"2017","journal-title":"Ann Am Thorac Soc"},{"issue":"3-b","key":"jrv240008r114","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.18553\/jmcp.2017.23.3-b.s17","article-title":"Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis.","volume":"23","author":"Fisher","year":"2017","journal-title":"J Manag Care Spec Pharm"},{"issue":"2","key":"jrv240008r115","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry.","volume":"49","author":"Jo","year":"2017","journal-title":"Eur Respir J"},{"issue":"4","key":"jrv240008r116","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01299-2023","article-title":"Real-world cohort evaluation of the impact of the antifibrotics in patients with idiopathic pulmonary fibrosis.","volume":"62","author":"Dempsey","year":"2023","journal-title":"Eur Respir J"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2817849\/jama_maher_2024_rv_240008_1715359937.95692.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T11:17:22Z","timestamp":1716290242000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2817849"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2024,5,21]]},"references-count":116,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2024,5,21]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2024.3669","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,21]]}}}